SGMO : Summary for Sangamo Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Sangamo Therapeutics, Inc. (SGMO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.95-0.15 (-3.66%)
At close: 4:00PM EST
People also watch
SGENALNYPGNXZIOPNBIX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4.10
Open4.15
Bid3.90 x 100
Ask4.05 x 100
Day's Range3.77 - 4.15
52 Week Range2.65 - 7.60
Volume1,667,003
Avg. Volume981,877
Market Cap278.96M
Beta2.86
PE Ratio (TTM)-3.66
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com6 days ago

    Biotech Premarket Movers: SGMO, IPXL, PTLA

    Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

  • TheStreet.com8 days ago

    Biotech Premarket Movers: IPXL, SGMO, ARLZ

    Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.

  • PR Newswire8 days ago

    Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I

    RICHMOND, Calif., Jan. 11, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. Orphan drug designations are granted to drugs and biologics intended to treat rare diseases. Using Sangamo's zinc finger nuclease (ZFN) genome editing technology, SB-318 is designed as a single treatment strategy intended to provide stable, continuous production of the IDUA enzyme for the lifetime of the patient.